Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPaul ChauvetGMGabriel E. MonsalveALAurore Lavigné

Discussion

Loading...

Member takes

Overview

Multivariate analysis shows CD8+ central-memory T cells predict response to CAR T-cell therapy in large B-cell lymphoma, highlighting key biomarkers.

Key Points

  • This research aims to identify predictors of treatment response to axicabtagene ciloleucel in large B-cell lymphoma patients.
  • Analyzed clinical and biological data from 60 heavily pre-treated large B-cell lymphoma patients
  • Utilized single-cell RNA sequencing and spectral flow cytometry to assess T cell profiles
  • Conducted multivariate analysis to identify predictors of treatment failure
  • Overall response rates were 76.7%, with complete response rates of 53.3%
  • Identified a baseline CD8+ central-memory T-cell signature predictive of resistance to CAR T-cell therapy
  • Patients with lower CD8+ CAR T cell counts had impaired cytotoxic functions, suggesting a tumor-driven adaptation

Cite This Study

Chauvet et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d62ehttps://doi.org/10.1182/blood-2025-1945
View Full Paper
Ask AI
Bookmark
Share